Last reviewed · How we verify

Epidural ropivacaine

Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor · Phase 3 active Small molecule

Epidural ropivacaine is a Local anesthetic (amide) Small molecule drug developed by Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor. It is currently in Phase 3 development for Epidural anesthesia for surgical procedures, Epidural analgesia for postoperative pain management.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia. Used for Epidural anesthesia for surgical procedures, Epidural analgesia for postoperative pain management.

At a glance

Generic nameEpidural ropivacaine
SponsorInstitutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhasePhase 3

Mechanism of action

Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in the neuronal cell membrane. This prevents depolarization and action potential generation in sensory and motor nerves. When administered epidurally, it diffuses across the dura to block nerve roots and spinal nerves, producing localized anesthesia and analgesia in the distribution of the affected nerves.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Epidural ropivacaine

What is Epidural ropivacaine?

Epidural ropivacaine is a Local anesthetic (amide) drug developed by Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor, indicated for Epidural anesthesia for surgical procedures, Epidural analgesia for postoperative pain management.

How does Epidural ropivacaine work?

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.

What is Epidural ropivacaine used for?

Epidural ropivacaine is indicated for Epidural anesthesia for surgical procedures, Epidural analgesia for postoperative pain management.

Who makes Epidural ropivacaine?

Epidural ropivacaine is developed by Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor (see full Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor pipeline at /company/institutul-regional-de-gastroenterologie-hepatologie-prof-dr-octavian-fodor).

What drug class is Epidural ropivacaine in?

Epidural ropivacaine belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is Epidural ropivacaine in?

Epidural ropivacaine is in Phase 3.

What are the side effects of Epidural ropivacaine?

Common side effects of Epidural ropivacaine include Hypotension, Bradycardia, Headache, Nausea, Neurological toxicity (at high doses).

What does Epidural ropivacaine target?

Epidural ropivacaine targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related